PMID- 31008964
OWN - NLM
STAT- MEDLINE
DCOM- 20190507
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 16
DP  - 2019 Apr
TI  - The clinical efficacy and safety of the Chinese herbal medicine Astragalus 
      (Huangqi) preparation for the treatment of acute myocardial infarction: A 
      systematic review of randomized controlled trials.
PG  - e15256
LID - 10.1097/MD.0000000000015256 [doi]
LID - e15256
AB  - BACKGROUND: In recent years, with the enormous advances in the field of cardiac 
      intervention technology, the survival rate of patients with acute myocardial 
      infarction (AMI) has been improved significantly. However, the risk of 
      arrhythmias and heart failure remains very high in AMI patients for long-term 
      prognosis. Chinese herbal medicine (CHM) is more and more used in the treatment 
      of AMI because of its good curative effect and less side effects. The target of 
      this research is to analyze the efficacy and safety of Astragalus (Huangqi) 
      preparation in the treatment of AMI by meta-analysis and also to provide a better 
      evidence for clinical practice. METHODS: Seven databases will be searched in this 
      study: The Cochrane Library, PubMed, Web of Science, the Chinese National 
      Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (CSJD), 
      the Chinese Biomedical Literature Database (CBM), and Wanfang DATA. The following 
      search terms will be used: (Huangqi OR Huang Qi OR Astragalus OR radix astragali) 
      AND (acute myocardial infaction OR myocardial infaction OR AMI) AND (randomized 
      controlled trial OR RCT OR randomized). No language limitations and the searches 
      will be conducted up to March, 2019. INCLUSION CRITERIA: randomized controlled 
      trial (RCT) of Astragalus (Huangqi) preparation in patients with AMI. Main 
      outcome measures will be left ventricular end systolic volume (LVESV), left 
      ventricular end diastolic volume (LVEDV), left ventricular ejection fraction 
      (LVEF), left ventricular mass index (LVMI), recanalization rate, mortality rate, 
      incidence of reperfusion arrhythmias, postinfarction angina pectoris, and 
      re-infarction rate. Secondary outcome indicators were the incidence of adverse 
      reactions and the effective rate of traditional Chinese medicine (TCM) treatment. 
      Two independent reviewers will filter the literature and extract data which based 
      to the Cochrane manual. The relevant data, including bias risk assessment, data 
      synthesis, subgroup analysis, meta-analysis, and final meta-analysis, will be 
      analyzed with RevMan 5.3 software. The funnel diagram will be used to evaluate 
      the reported deviation, and the Egger test will be used to evaluate the symmetry 
      of the funnel graph. RESULTS: This systematic review study will provide a clear 
      basis for evaluating the efficacy and safety of Astragalus (Huangqi) preparation 
      with the treatment of AMI. CONCLUSION: This study will provide an up-to-date 
      evidence for evaluating the efficacy and safety of Astragalus (Huangqi) 
      preparation. PROSPERO REGISTRATION NUMBER: CRD42019124843.
FAU - Zhang, Yuqin
AU  - Zhang Y
AD  - School of Chinese Medicine.
FAU - Wu, Jiani
AU  - Wu J
AD  - School of Chinese Medicine.
FAU - Guo, Shuwen
AU  - Guo S
AD  - Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China.
FAU - Lin, Wangou
AU  - Lin W
AD  - School of Chinese Medicine.
FAU - Zhang, Binyue
AU  - Zhang B
AD  - School of Chinese Medicine.
FAU - Chen, Xi
AU  - Chen X
AD  - School of Chinese Medicine.
FAU - Mo, Hanrong
AU  - Mo H
AD  - School of Chinese Medicine.
FAU - Zhan, Tianwei
AU  - Zhan T
AD  - School of Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (huangqi decoction)
SB  - IM
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Randomized Controlled Trials as Topic
PMC - PMC6494254
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/04/23 06:00
MHDA- 2019/05/08 06:00
PMCR- 2019/04/19
CRDT- 2019/04/23 06:00
PHST- 2019/04/23 06:00 [entrez]
PHST- 2019/04/23 06:00 [pubmed]
PHST- 2019/05/08 06:00 [medline]
PHST- 2019/04/19 00:00 [pmc-release]
AID - 00005792-201904190-00045 [pii]
AID - MD-D-19-02194 [pii]
AID - 10.1097/MD.0000000000015256 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Apr;98(16):e15256. doi: 10.1097/MD.0000000000015256.